This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of
IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation
(CD)19 and CD20 in participants with aggressive B-cell NHL.
Up to 30 patients will be enrolled in dose finding Phase 1 part of the study, which will
determine the recommended phase 2 dose.
Phase 2 will enroll 20 additional participants to evaluate further the safety and efficacy of
IMPT-314.
IMPT-314 treatment consists of a single infusion of CAR-transduced autologous T cells
administered intravenously after a conditioning chemotherapy regimen consisting of
fludarabine and cyclophosphamide, administered over 3 days.
Individual participants will remain in the active post-treatment period for approximately 2
years. Participants will continue in long-term follow-up for 15 years from treatment.